Potential targets for tumor-specific imaging of vulvar squamous cell carcinoma: A systematic review of candidate biomarkers.

[1]  Kee W. Tan,et al.  Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  Pieterjan Debie,et al.  Latest developments in molecular tracers for fluorescence image-guided cancer surgery. , 2019, The Lancet. Oncology.

[3]  Xiao Lin,et al.  Combination of PET and CXCR4-Targeted Peptide Molecule Agents for Noninvasive Tumor Monitoring , 2019, Journal of Cancer.

[4]  Gowri Rangaswamy Gunassekaran,et al.  Peptide-based targeted therapeutics and apoptosis imaging probes for cancer therapy , 2019, Archives of Pharmacal Research.

[5]  W. L. Turnbull,et al.  A dual modality 99mTc/Re(i)-labelled T140 analogue for imaging of CXCR4 expression. , 2019, Organic & biomolecular chemistry.

[6]  P. Hogendoorn,et al.  Introducing fluorescence guided surgery into orthopedic oncology: A systematic review of candidate protein targets for Ewing sarcoma , 2018, Journal of surgical oncology.

[7]  M. Schwaiger,et al.  PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma , 2018, EJNMMI Research.

[8]  P. Friedl,et al.  Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma , 2018, Scientific Reports.

[9]  J. Salleron,et al.  Photodynamic diagnosis with methyl-5-aminolevulinate in squamous intraepithelial lesions of the vulva: Experimental research , 2018, PloS one.

[10]  H. Hollema,et al.  Prognostic factors for local recurrence of squamous cell carcinoma of the vulva: A systematic review. , 2017, Gynecologic oncology.

[11]  E. De Ponti,et al.  18F-FDG PET/CT in preoperative staging of vulvar cancer patients: is it really effective? , 2017, Medicine.

[12]  J. Nilvebrant,et al.  CD44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches , 2017, Contrast media & molecular imaging.

[13]  F. Ghezzi,et al.  Predictors and Patterns of Local, Regional, and Distant Failure in Squamous Cell Carcinoma of the Vulva , 2017, American journal of clinical oncology.

[14]  E. Bahassi,et al.  Comparative molecular profiling of HPV‐induced squamous cell carcinomas , 2017, Cancer medicine.

[15]  ping wang,et al.  Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer , 2017, Oncotarget.

[16]  C. V. D. van de Velde,et al.  Preclinical uPAR-targeted multimodal imaging of locoregional oral cancer. , 2017, Oral oncology.

[17]  Binbin Xie,et al.  Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis , 2017, Oncotarget.

[18]  N. Harlaar,et al.  Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study. , 2016, The lancet. Gastroenterology & hepatology.

[19]  K. Gaarenstroom,et al.  Risk factors and treatment for recurrent vulvar squamous cell carcinoma. , 2016, Critical reviews in oncology/hematology.

[20]  M. Salzberg,et al.  A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. , 2016, European journal of cancer.

[21]  P. Thaker,et al.  Identification of molecular targets in vulvar cancers. , 2016, Gynecologic oncology.

[22]  Cristina Martelli,et al.  Optical imaging probes in oncology , 2016, Oncotarget.

[23]  P. Kuppen,et al.  Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins , 2016, Biomarkers in cancer.

[24]  E. Oliva,et al.  Squamous Cell Carcinoma of the Vulva: A Subclassification of 97 Cases by Clinicopathologic, Immunohistochemical, and Molecular Features (p16, p53, and EGFR) , 2015, The American journal of surgical pathology.

[25]  A. van der Zee,et al.  Sentinel node biopsy in vulvar cancer: Implications for staging. , 2015, Best practice & research. Clinical obstetrics & gynaecology.

[26]  Joshua S Richman,et al.  Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer , 2015, Clinical Cancer Research.

[27]  P. Shekelle,et al.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement , 2015, Systematic Reviews.

[28]  P. Vaupel,et al.  GLUT-1 expression is largely unrelated to both hypoxia and the Warburg phenotype in squamous cell carcinomas of the vulva , 2014, BMC Cancer.

[29]  P. Mukherjee,et al.  MUC1: a multifaceted oncoprotein with a key role in cancer progression. , 2014, Trends in molecular medicine.

[30]  R. Rocha,et al.  EGFR expression in vulvar cancer: clinical implications and tumor heterogeneity. , 2014, Human pathology.

[31]  M. Biffoni,et al.  CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. , 2014, Cell stem cell.

[32]  A. Mercurio,et al.  VEGF targets the tumour cell , 2013, Nature Reviews Cancer.

[33]  N. Muñoz,et al.  Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. , 2013, European journal of cancer.

[34]  J. Nesland,et al.  Primary Tumor Vascularity, HIF-1α and VEGF expression in vulvar squamous cell carcinomas: their relationships with clinicopathological characteristics and prognostic impact , 2013, BMC Cancer.

[35]  D. Shahbazi-Gahrouei,et al.  Detection of MUC1-Expressing Ovarian Cancer by C595 Monoclonal Antibody-Conjugated SPIONs Using MR Imaging , 2013, TheScientificWorldJournal.

[36]  T. Ikeda,et al.  Association of CXC Chemokine Receptor Type 4 Expression and Clinicopathologic Features in Human Vulvar Cancer , 2013, International Journal of Gynecologic Cancer.

[37]  Xia Li,et al.  Expression of endogenous hypoxia markers in vulvar squamous cell carcinoma. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[38]  T. Buckle,et al.  Imaging agents for the chemokine receptor 4 (CXCR4). , 2012, Chemical Society reviews.

[39]  R. Simon,et al.  EGFR gene copy number increase in vulvar carcinomas is linked with poor clinical outcome , 2011, Journal of Clinical Pathology.

[40]  Pamela E. Constantinou,et al.  Transmembrane mucins as novel therapeutic targets , 2011, Expert review of endocrinology & metabolism.

[41]  Jianting Zhang,et al.  Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical application. , 2011, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.

[42]  Lucia M. A. Crane,et al.  Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target Identification Tool. , 2011, Translational oncology.

[43]  J. Kaanders,et al.  Hemoglobin level predicts outcome for vulvar cancer patients independent of GLUT-1 and CA-IX expression in tumor tissue , 2010, Virchows Archiv.

[44]  S. Devaskar,et al.  Will the original glucose transporter isoform please stand up! , 2009, American journal of physiology. Endocrinology and metabolism.

[45]  M. Janier,et al.  Influence of multidrug resistance on 18F-FCH cellular uptake in a glioblastoma model , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[46]  Eva Sevick-Muraca,et al.  Characterization and performance of a near-infrared 2-deoxyglucose optical imaging agent for mouse cancer models. , 2009, Analytical Biochemistry.

[47]  M. Burger,et al.  Validation of Tissue Microarray Technology in Vulvar Cancer , 2009, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[48]  Giampiero Girolomoni,et al.  The epidermal growth factor receptor system in skin repair and inflammation. , 2008, The Journal of investigative dermatology.

[49]  H. Brustmann.  Epidermal Growth Factor Receptor Is Involved in the Development of an Invasive Phenotype in Vulvar Squamous Lesions, but Is Not Related to MIB-1 Immunoreactivity , 2007, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[50]  A. Perkins,et al.  Radiolabelled aptamers for tumour imaging and therapy. , 2007, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[51]  M. Burger,et al.  Identification of Potential Prognostic Markers for Vulvar Cancer Using Immunohistochemical Staining of Tissue Microarrays , 2007, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[52]  N. Park,et al.  Increased Cyclooxygenase‐2 Expression Associated with Inflammatory Cellular Infiltration in Elderly Patients with Vulvar Cancer , 2007, Annals of the New York Academy of Sciences.

[53]  K. Moghissi,et al.  Initial experience of the use of photodynamic therapy (PDT) in recurrent malignant and pre-malignant lesions of the vulva. , 2006, Photodiagnosis and photodynamic therapy.

[54]  Y. Assaraf,et al.  Targeting an extracellular epitope of the human multidrug resistance protein 1 (MRP1) in malignant cells with a novel recombinant single chain Fv antibody , 2004, International journal of cancer.

[55]  S. Yonezawa,et al.  Expression of epithelial growth factor receptor and its two ligands, transforming growth factor-alpha and epithelial growth factor, in normal and neoplastic squamous cells in the vulva: an immunohistochemical study , 2001, Medical Electron Microscopy.

[56]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[57]  G. Snow,et al.  Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  P. Speiser,et al.  CD44v3 and v6 variant isoform expression correlates with poor prognosis in early-stage vulvar cancer. , 1998, British Journal of Cancer.

[59]  K. Min,et al.  Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. , 1997, Gynecologic oncology.

[60]  C. Kainz,et al.  Influence of microvessel density and vascular permeability factor/vascular endothelial growth factor expression on prognosis in vulvar cancer. , 1996, Gynecologic oncology.

[61]  C. Kainz,et al.  Prognostic value of immunohistochemically detected CD44 expression in patients with carcinoma of the vulva , 1996, Cancer.

[62]  S. Fox,et al.  Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. , 1994, Cancer research.

[63]  S. Choi,et al.  MRI molecular imaging using GLUT1 antibody-Fe3O4 nanoparticles in the hemangioma animal model for differentiating infantile hemangioma from vascular malformation. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[64]  Hongyan Liu,et al.  CD44 expression is predictive of poor prognosis in pharyngolaryngeal cancer: systematic review and meta-analysis. , 2014, The Tohoku journal of experimental medicine.

[65]  H. Hollema,et al.  EGFR expression is associated with groin node metastases in vulvar cancer, but does not improve their prediction. , 2007, Gynecologic oncology.

[66]  M. Haber,et al.  Role of the MRP1/ABCC1 Multidrug Transporter Protein in Cancer , 2007, IUBMB life.

[67]  P. Speiser,et al.  The prognostic value of immunohistochemically detected CD44v3 and CD44v6 expression in patients with surgically staged vulvar carcinoma , 2002, Cancer.

[68]  S. Yonezawa,et al.  Expression of Mucin 1(MUC1)in Benign, Premalignant and Malignant Vulvar Tumors , 2000 .